Cargando…

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for treating hyperglycemia in patients with type 2 diabetes not adequately...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ratner, Robert, Han, Jenny, Nicewarner, Dawn, Yushmanova, Irina, Hoogwerf, Byron J, Shen, Larry
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070629/ https://www.ncbi.nlm.nih.gov/pubmed/21410975 http://dx.doi.org/10.1186/1475-2840-10-22

Ejemplares similares

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
por: Gill, Anne, et al.
Publicado: (2010)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis
por: Hoogwerf, Byron J., et al.
Publicado: (2016)

Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study
por: Simó, Rafael, et al.
Publicado: (2015)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
por: Kiiskinen, Urpo, et al.
Publicado: (2013)

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
por: Gaebler, Julia A, et al.
Publicado: (2012)

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals
por: Meloni, Alison R, et al.
Publicado: (2013)

Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
por: Torimoto, Keiichi, et al.
Publicado: (2015)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
por: Best, Jennie H., et al.
Publicado: (2011)

Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes
por: Blonde, Lawrence, et al.
Publicado: (2015)

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
por: Paul, Sanjoy K, et al.
Publicado: (2015)

Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
por: Kelly, Aaron S, et al.
Publicado: (2012)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
por: Clegg, Lindsay E., et al.
Publicado: (2019)

The effects of basal insulin peglispro vs. insulin glargine on lipoprotein particles by NMR and liver fat content by MRI in patients with diabetes
por: Orchard, Trevor J., et al.
Publicado: (2017)

Efficacy and safety of exenatide once‐weekly vs exenatide twice‐daily in Asian patients with type 2 diabetes mellitus
por: Ji, Linong, et al.
Publicado: (2013)

Efficacy and safety of once‐weekly exenatide after switching from twice‐daily exenatide in patients with type 2 diabetes
por: Watanabe, Yuusuke, et al.
Publicado: (2019)

Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
por: Guja, Cristian, et al.
Publicado: (2020)

PyBIDS: Python tools for BIDS datasets
por: Yarkoni, Tal, et al.
Publicado: (2019)

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom
por: Woehl, Anette, et al.
Publicado: (2008)

Correction to: Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease
por: Guja, Cristian, et al.
Publicado: (2020)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell, Leigh, et al.
Publicado: (2015)

Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production
por: Sélley, Eszter, et al.
Publicado: (2014)

Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine
por: Chen, Weena J. Y., et al.
Publicado: (2017)

Bidding adieu
por: Verma, Shyam
Publicado: (2015)

Bidding Adieu…
por: Desai, Chetna
Publicado: (2017)

Bid Adieu……
por: Agarwal, Sanjay Kumar
Publicado: (2022)

A dynamic novel approach for bid/no-bid decision-making
por: Shi, Huawang, et al.
Publicado: (2016)

Curation of BIDS (CuBIDS): A workflow and software package for streamlining reproducible curation of large BIDS datasets
por: Covitz, Sydney, et al.
Publicado: (2022)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Exenatide can inhibit calcification of human VSMCs through the NF-kappaB/RANKL signaling pathway
por: Zhan, Jun-Kun, et al.
Publicado: (2014)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
por: Davis, Timothy M. E., et al.
Publicado: (2022)

MNE-BIDS: Organizing electrophysiological data into the BIDS format and facilitating their analysis
por: Appelhoff, Stefan, et al.
Publicado: (2019)

Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials
por: MacConell, Leigh, et al.
Publicado: (2012)

The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats
por: Liu, Que, et al.
Publicado: (2010)

Variability in and predictors of glycaemic responses after 24 weeks of treatment with exenatide twice daily and exenatide once weekly
por: Shaw, Jonathan E., et al.
Publicado: (2017)

Creating Winning Bids
por: Sawczuk, Basil
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mi2nr4mcg42qfegsq2dn65e8pe